We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Haleon | HLN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.10 | 0.03% | 373.40 | 16:35:02 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 372.60 | 370.90 | 375.90 | 373.40 | 373.30 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 01/08/2024 | Interim | GBP | 0.02 | 15/08/2024 | 16/08/2024 | 19/09/2024 |
| 29/02/2024 | Final | GBP | 0.042 | 14/03/2024 | 15/03/2024 | 16/05/2024 |
| 02/08/2023 | Interim | GBP | 0.018 | 24/08/2023 | 25/08/2023 | 05/10/2023 |
| 02/03/2023 | Final | GBP | 0.024 | 16/03/2023 | 17/03/2023 | 27/04/2023 |
| Top Posts |
|---|
Posted at 14/11/2024 12:25 by anhar Forward yield for 25 is only about 2% at 362p and a forecast 7.2p divi. |
Posted at 14/11/2024 09:56 by anhar As an income investor I won't be adding at the current very low yield. Even a big rise in the divis of say 50% would still leave the yield too low for me to increase my holding with the share price around the present level. For most purchases, either top-ups or new holdings, I like to target a yield of at least 5% in current market conditions though I sometimes make exceptions to this for portfolio and diversification reasons.I continue though to retain my holding from the GSK demerger as I think HLN has decent potential divi growth and my favoured approach is to to nothing. |
Posted at 05/11/2024 11:02 by philanderer Berenberg: Haleon on road to growthHaleon (HLN), the consumer health group spun out of GSK, is en route to a more ‘balanced growth algorithm’, says Berenberg. Analyst Bethan Davies retained her ‘buy’ recommendation and increased the target price marginally from 454p to 456p on the Citywire Elite Companies A-rated owner of brands such as Sensodyne and Panadol, which softened 0.2% to 371.4p yesterday, but is and is up 17% since listing in 2022. Davies said catalysts for the stock price were becoming ‘increasingly visible’ and she is expecting volume growth to accelerate in the fourth quarter to 3.6% from 2.8% in the third quarter. Erectile dysfunction drug Eroxon has also been launched in the US and she expects this to contribute to organic sales growth next year. On top of this, management is planning a capital markets day in the first half of next year, ‘which we expect will remind investors of the structural growth opportunities within Haleon’s core categories’. ‘We continue to see an additional optionality from a post-overhang re-rating as Pfizer continues to sell down its stake in Haleon,’ she said. citywire.com |
Posted at 01/10/2024 09:09 by philanderer Pfizer's holding of HLN will now be down to appx 15% after these transactions. |
Posted at 30/9/2024 23:40 by philanderer And HLN buying £230 million worth from Pfizer subject to completion of Pfizer's offering |
Posted at 26/9/2024 11:03 by justiceforthemany The dividend is pathetic here. |
Posted at 25/9/2024 11:03 by anhar Yes they have. As you say HLN has shown high growth, in my case against my personal demerger tax base cost of about 249p. That figure will vary for everyone as it depends on their original cost of old GSK.But as I've said I'm only in shares for the divis and as such have been running an income port for decades, not for capital gains, though the latter are of course welcome. I hold very long term in most cases and will definitely be retaining my HLN stock. |
Posted at 24/9/2024 18:04 by laurence llewelyn binliner #Anhar, they have done well have they not, 273-395 pence for me since July 2022 which makes up for the small dividend, but we should hit the 2.5X net debt/EBITDA leverage target this period and it could be the dividend steps up again.. :o) |
Posted at 24/9/2024 09:58 by anhar I'd add bid potential to the reasons for the high rating. There was already an abortive bid from Unilever just prior to the GSK demerger so I expect many people think that HLN may be taken out at some stage.I retained my demerger HLN shares which have shown excellent growth, driving up the rating, though I'm just an income investor and it has demonstrated decent divi growth over its short independent existence. |
Posted at 24/9/2024 07:25 by laurence llewelyn binliner Buy backsDebt leverage reduction Annual organic revenue growth of 4-6% Organic operating profit growth ahead of organic revenue growth Net debt/adjusted EBITDA of around 2.5x Dividend to grow at least in line with adjusted earnings |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
